Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced the adoption of its Blood Volume Analysis (BVA) technology by three new hospitals. The expansion includes both the company's CLIA-certified ezBVA Lab service and on-site blood volume analyzers.
The new facilities include a Tennessee medical center adopting ezBVA Lab services for cardiology, a major Arkansas hospital implementing an on-site analyzer, and a leading referral hospital serving Arizona, Nevada, and Utah utilizing the ezBVA Lab service for heart failure patients. The company expects continued sales growth throughout 2025 as clinicians increasingly recognize BVA's benefits for optimizing fluid management.
Positive
- Expansion into three new prestigious healthcare facilities
- Dual revenue streams from both ezBVA Lab services and on-site analyzers
- Growing market penetration across multiple U.S. regions
- Management expects accelerated sales growth throughout 2025
Negative
- None.
Insights
Daxor's expansion into three new hospitals signals growing market acceptance and revenue growth potential for its blood volume analysis technology.
Daxor Corporation's expansion into three new hospitals represents a significant commercial milestone for its blood volume analysis (BVA) technology. The company is penetrating the market through dual deployment strategies: their CLIA-certified ezBVA Lab service providing next-day results and on-site blood volume analyzers at healthcare facilities.
The three new adoptions span different geographic regions (Tennessee, Arkansas, and a multi-state serving facility for Arizona, Nevada, and Utah), indicating broad regional acceptance rather than just localized success. Each implementation targets both inpatient and outpatient cardiology applications, particularly focusing on heart failure management - a high-cost, high-mortality condition where precise fluid management is critical.
This expansion carries particular significance in the medical device sector where adoption cycles are typically lengthy and require substantial clinical validation. That Daxor is securing placements across both community and major referral hospitals suggests the technology is gaining traction across different tiers of the healthcare system.
The dual-deployment approach (ezBVA Lab service and on-site analyzers) represents a flexible business model that can accommodate different hospital needs and budgets, potentially accelerating adoption. The technology addresses the critical clinical challenge of fluid management in heart failure patients, where both over and under-treatment lead to adverse outcomes and increased costs.
While specific financial projections aren't provided, the announcement's timing and the management's expectation of "accelerated sales growth" throughout 2025 suggests positive revenue momentum that may translate to improved financial performance in upcoming quarters.
Continued Integration of Daxor’s ezBVA Lab Service and On-Site Analyzers Fuels Positive Outlook
Oak Ridge, TN, July 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology into three new hospitals, a testament to the growing recognition of BVA's essential role in improving lives and reducing healthcare costs. This growth is driven by a combination of Daxor's state-of-the-art CLIA-certified ezBVA Lab service, which delivers on-demand, next-day blood volume analysis results, and an on-site placement of its blood volume analyzer. The company expects accelerated sales growth to continue throughout 2025 as clinicians increasingly embrace the benefits of BVA for optimizing fluid management decisions.
Recent sales wins include:
- Expansion into a key Tennessee medical center within a large integrated community healthcare system in the Appalachian Highlands, is adopting ezBVA Lab services for inpatient and outpatient cardiology applications
- A major hospital serving Arkansas is integrating BVA with an on-site analyzer to enhance its advanced heart care programs for both inpatient and outpatient settings
- A leading referral hospital serving Arizona, Nevada and Utah is utilizing Daxor’s ezBVA Lab service for its advanced heart failure patients, both inpatient and outpatient
“We are incredibly proud to announce the expansion of our BVA technology into three renowned facilities as a testament to the growing recognition of BVA's pivotal role in improving lives and reducing healthcare costs,” said Michael Feldschuh, Daxor Corporation CEO and President. “This momentum, driven by the increasing integration of our ezBVA Lab Service and on-site analyzers, underscores our commitment to providing clinicians, regardless of location, with precise tools to guide optimal fluid management.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What new facilities has Daxor (DXR) added for its Blood Volume Analysis technology in 2025?
How does Daxor's (DXR) Blood Volume Analysis technology generate revenue?
What is the expected growth outlook for Daxor (DXR) in 2025?
What applications are hospitals using Daxor's (DXR) BVA technology for?
